Skip to main
MDXG

MiMedx Group (MDXG) Stock Forecast & Price Target

MiMedx Group (MDXG) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 33%
Buy 67%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

MiMedx Group Inc has increased its 2025 revenue estimate to $387.3 million from $374.0 million, reflecting strong second-quarter results and significant growth in its surgical business. The company reported revenue of $98.6 million for the most recent quarter, achieving a year-over-year growth of approximately 13%, with notable contributions from the wound portfolio and surgical segments, which grew by 12% and 15%, respectively. Although selling, general, and administrative expenses rose roughly 16% year-over-year to $64.2 million due to higher sales commission rates and legal costs, the overall revenue trajectory indicates a positive growth outlook for MiMedx Group.

Bears say

MiMedx Group Inc's gross margin has decreased to approximately 81%, down from 83% in the previous quarter, a trend attributed to production variances and changes in product mix. Although the company maintains guidance of achieving low double-digit percentage year-over-year revenue growth and an adjusted EBITDA margin above 20%, these forecasts may be overshadowed by external risks. Furthermore, potential negative changes in reimbursement rates by CMS could significantly adversely impact the firm's financial performance, contributing to a negative outlook.

MiMedx Group (MDXG) has been analyzed by 3 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 67% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MiMedx Group and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MiMedx Group (MDXG) Forecast

Analysts have given MiMedx Group (MDXG) a Buy based on their latest research and market trends.

According to 3 analysts, MiMedx Group (MDXG) has a Buy consensus rating as of Feb 7, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MiMedx Group (MDXG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.